grant
Human natural killer cells: Advancing biology and clinical applications
Organization BECKMAN RESEARCH INSTITUTE/CITY OF HOPELocation DUARTE, UNITED STATESPosted 21 Jul 2017Deadline 30 Jun 2032
NIHUS FederalResearch GrantFY2025AddressAllogenicAuthorshipAwardBiological MarkersBiologyBiotechBiotechnologyCAR NKCancer CauseCancer EtiologyCancer PatientCancer TreatmentCancersCell BodyCell TherapyCellsCessation of lifeClinicCytotoxic cellDeathDevelopmentFundingFunding AgencyFunding SourceGastroenterologyHumanHuman BiologyIL-15IL15IL15 ProteinImmuneImmunesImmunityImmunologyInstitutionInterleukin-15Interleukin-15 PrecursorJournalsK lymphocyteKnowledgeLymphoid CellMGC9721MagazineMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant Pancreatic NeoplasmMalignant TumorMalignant neoplasm of pancreasMemoryMinorModern ManModificationMolecularNK CellsNK cell immune therapyNK cell immunotherapyNK cell therapyNK cell treatmentNK cell-based immune therapyNK cell-based immunotherapyNK cell-based therapyNK cell-based treatmentNK cellular immunotherapyNK cellular therapyNK immunotherapyNK therapyNK treatmentNatural Killer Cell ImmunotherapyNatural Killer CellsNaturePancreas CancerPancreatic CancerPropertyPublicationsPublishingSafetyScienceScientific PublicationSolid NeoplasmSolid TumorSurvival RateT-CellsT-LymphocyteTranslatingWorkanti-cancer therapybio-markersbiologic markerbiomarkercancer therapycancer-directed therapycell based interventioncell mediated interventioncell mediated therapiescell-based therapeuticcell-based therapycellular therapeuticcellular therapychimeric antigen receptorchimeric antigen receptor engineered natural killer cellchimeric antigen receptor natural killer cellsclinical applicabilityclinical applicationclinical efficacyclinical translationclinically translatablecost effectivedevelopmentalengineered NK cellengineered natural killer cellexhaustionimprovedin vivo Modelinnovateinnovationinnovativemalignancynatural killer cell based immune therapynatural killer cell based immunotherapynatural killer cell therapynatural killer cell treatmentnatural killer cell-based therapynatural killer cells expressing chimeric antigen receptorsnatural killer cells with chimeric antigen receptorsnatural killer cellular therapynatural killer therapyneoplasm/cancernew approachesnovel approachesnovel strategiesnovel strategypancreatic cancer patientspancreatic malignancypatients with pancreatic cancerthymus derived lymphocytetraffickingtumor
Get Agency plan to apply$29.99/mo · 7-day free trial · pipeline · alerts
or
— or —Get email alerts for similar roles
Description preview
PROJECT SUMMARY
The current R35 competitive renewal is revised from 2023 (Score 15). The Panel and Reviewers raised 5 “minor”
(the word used in the Summary Statement) weaknesses that I addressed. I have studied the basic biology of
human natural killer (NK) cells and their clinical application for cancer treatment over the past 33 years. Basic…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click